4-[(aminooxy)methyl]benzonitrile | 1782-39-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(aminooxy)methyl]benzonitrile
• 英文别名: O-(4-cyanobenzyl)hydroxylamine；O-(4-cyanobenzyl)-hydroxylamine hydrochloride；4-(aminooxymethyl)benzonitrile
• CAS: 1782-39-4
• 化学式: C₈H₈N₂O
• 分子量: 148.164
• InChiKey: ATBANLOLDZIUOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(aminooxy)methyl]benzonitrile 在 盐酸 、 氨 作用下， 以 甲醇 为溶剂， 反应 38.0h， 生成 4-[(aminooxy)methyl]benzenecarboximidamide
  参考文献：
  名称：

  [EN] AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
  [FR] COMPOSÉS DE BÊTA-LACTAME À SUBSTITUTION AMIDINE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS

  摘要：

  本发明涉及式(I)的新型β-内酰胺化合物，它们的制备和使用。特别是，本发明涉及作为抗菌剂有用的新型β-内酰胺化合物，即取代脒的单巴坦衍生物及其制备方法。

  公开号：

  WO2013110643A1
• 作为产物：
  描述：

  4-(羟甲基)苯甲腈 在 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 30.0h， 生成 4-[(aminooxy)methyl]benzonitrile
  参考文献：
  名称：

  [EN] AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
  [FR] COMPOSÉS DE BÊTA-LACTAME À SUBSTITUTION AMIDINE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS

  摘要：

  本发明涉及式(I)的新型β-内酰胺化合物，它们的制备和使用。特别是，本发明涉及作为抗菌剂有用的新型β-内酰胺化合物，即取代脒的单巴坦衍生物及其制备方法。

  公开号：

  WO2013110643A1

文献信息

• Synthesis, Crystal Structure, Herbicidal Activity, and SAR Study of Novel <i>N</i>-(Arylmethoxy)-2-chloronicotinamides Derived from Nicotinic Acid
  作者：Chen-Sheng Yu、Qiao Wang、Joanna Bajsa-Hirschel、Charles L. Cantrell、Stephen O. Duke、Xing-Hai Liu

  DOI：10.1021/acs.jafc.0c07538

  日期：2021.6.16

  animals. To discover novel natural-product-based herbicides, a series of N-(arylmethoxy)-2-chloronicotinamides were designed and synthesized. Some of the new N-(arylmethoxy)-2-chloronicotinamides exhibited excellent herbicidal activity against Agrostis stolonifera (bentgrass) at 100 μM. Compound 5f (2-chloro-N-((3,4-dichlorobenzyl)oxy)nicotinamide) possessed excellent herbicidal activity against Lemna paucicostata

  烟酸又称烟酸，是一种天然产物，广泛存在于动植物中。为了发现基于天然产物的新型除草剂，设计并合成了一系列N- (芳基甲氧基)-2-氯代烟酰胺。一些新的N -(芳基甲氧基)-2-氯烟酰胺在 100 μM 时对Agrostis stolonifera（蓼蒿）表现出优异的除草活性。化合物5F（2-氯- ñ - （（3,4-二氯苄基）氧基）烟酰胺）具有优良的除草活性对青萍（浮萍），与IC 50值 7.8 μM，而商业除草剂异恶草酮和丙苯腈的值分别为 125 和 2 μM。本文报道的构效关系可用于开发抗单子叶杂草的新型除草剂。
• Design, Synthesis, Molecular Docking and Biological Evaluation of Novel Coumarin-Oxime Ether Derivatives as COX-2 Inhibitors
  作者：M. Vijaya Bhargavi、P. Shashikala、M. Sumakanth、Shravan Kumar Gunda

  DOI：10.14233/ajchem.2017.20865

  日期：——

  Coumarin-oxime ether derivatives (14-25) were synthesized by an efficient and straight forward procedure from the reaction of 3-acetyl coumarin (1) and o-substituted benzyl hydroxyl amines (2-13) in pyridinium p-toluenesulfonate/dichloromethane (PPTS/DCM) at reflux temperature. High yields and simple operations are important features of this methodology. The method is very useful for the construction of many biologically active oxime ether derivatives. The structures of the synthesized compounds are established based on IR, NMR and MASS spectrometry. Molecular docking studies were performed against selective COX-2 enzyme using Discovery Studio v3.5. The compounds with good LibDock score were screened for their in vivo anti-inflammatory activity by paw edema method, employing indomethacin as a reference standard.

  香豆素-肟醚衍生物（14-25）是由 3-乙酰基香豆素（1）和邻取代苄基羟胺（2-13）在吡啶对甲苯磺酸盐/二氯甲烷（PPTS/DCM）中于回流温度下反应合成的，该过程高效且简单。产量高、操作简单是该方法的重要特点。该方法非常适用于制造许多具有生物活性的肟醚衍生物。根据红外光谱、核磁共振和质谱分析，确定了合成化合物的结构。使用 Discovery Studio v3.5 针对选择性 COX-2 酶进行了分子对接研究。以吲哚美辛为参考标准，采用爪水肿法对 LibDock 得分较高的化合物进行了体内抗炎活性筛选。
• Carbonyl compound scavenger and method of quantifying carbonyl compound using the same
  申请人：Kitasaka Kazuya

  公开号：US20060275913A1

  公开（公告）日：2006-12-07

  A carbonyl compound scavenger comprising a mineral acid salt of a benzylhydroxyamine-based compound of the formula (1) and at least one adsorbent selected from the group consisting of silica gel, alumina, cellulose and activated carbon: [wherein, R represents an alkyl group having 1 to 8 carbon atoms, haloalkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, haloalkoxy group having 1 to 4 carbon atoms, nitro group or cyano group, and R 1 and R 2 represent each independently a hydrogen atom or alkyl group having 1 to 8 carbon atoms, and a hydrogen atom on a benzene ring to which a cyano group and R are connected may be substituted with an alkyl group having 1 to 8 carbon atoms, haloalkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, haloalkoxy group having 1 to 4 carbon atoms, aryl group having 6 to 10 carbon atoms, nitro group or cyano group.].

  一种含有矿物酸盐的羰基化合物清除剂，其由公式（1）的苄基羟胺化合物的矿物酸盐和至少一种吸附剂组成，所述吸附剂选自硅胶、氧化铝、纤维素和活性炭的组中：[其中，R代表具有1至8个碳原子的烷基、具有1至4个碳原子的卤代烷基、具有1至4个碳原子的烷氧基、具有1至4个碳原子的卤代烷氧基、硝基或氰基，R1和R2各自独立地表示氢原子或具有1至8个碳原子的烷基，以及连接氰基和R的苯环上的氢原子可以被具有1至8个碳原子的烷基、具有1至4个碳原子的卤代烷基、具有1至4个碳原子的烷氧基、具有1至4个碳原子的卤代烷氧基、具有6至10个碳原子的芳基、硝基或氰基取代。]
• Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof
  申请人：Fensholdt Jef

  公开号：US20070244117A1

  公开（公告）日：2007-10-18

  The invention relates to compounds of general formula I wherein D, E, F, G, W, Y, R 1 , A, R 9 , X, B, R 8 are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer.

  本发明涉及一般式I的化合物，其中D、E、F、G、W、Y、R1、A、R9、X、B、R8如本文所定义，并且其药学上可接受的盐、水合物或溶剂化物，用于治疗与异常血管生成相关的疾病，如癌症，可单独使用或与一个或多个其他药理活性化合物联合使用。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。